Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+ T cells in African adults

Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+ T cells in African adults

We are developing a pan-clade HIV-1 T-cell vaccine HIVconsv, which could complement Env vaccines for prophylaxis and be a key to HIV cure. Our strategy focuses vaccine-elicited effector T-cells on functionally and structurally conserved regions (not full-length proteins and not only epitopes) of the...

Full description

Bibliographic Details
Main Authors:	Gaudensia Mutua, Bashir Farah, Robert Langat, Jackton Indangasi, Simon Ogola, Brian Onsembe, Jakub T Kopycinski, Peter Hayes, Nicola J Borthwick, Ambreen Ashraf, Len Dally, Burc Barin, Annika Tillander, Jill Gilmour, Jan De Bont, Alison Crook, Drew Hannaman, Josephine H Cox, Omu Anzala, Patricia E Fast, Marie Reilly, Kundai Chinyenze, Walter Jaoko, Tomáš Hanke
Format:	Article
Language:	English
Published:	Elsevier 2016-01-01
Series:	Molecular Therapy: Methods & Clinical Development
Online Access:	http://www.sciencedirect.com/science/article/pii/S2329050117300311

Similar Items

Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+ T cells in African adults
by: Mutua, G, et al.
Published: (2017)

Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+T cells in African adults
by: Cox, J, et al.
Published: (2016)

Acceptability and feasibility of repeated mucosal specimen collection in clinical trial participants in Kenya.
by: Gloria Omosa-Manyonyi, et al.
Published: (2014-01-01)

Early antiretroviral therapy and its impact on natural killer cell dynamics in HIV-1 infected men who have sex with men: a cross-sectional pilot study evaluating the impact of early ART initiation on NK cell perturbation in HIV infection
by: Matrona Akiso, et al.
Published: (2024-04-01)

Cultured enzyme-linked immunospot assay (ELISPOT) enhances detection of low HIV-specific immune responses in exposed seronegative individuals in Kenya
by: Anzala Omu, et al.
Published: (2006-12-01)

Acceptability and tolerability of repeated intramuscular electroporation of Multi-antigenic HIV (HIVMAG) DNA vaccine among healthy African participants in a phase 1 randomized controlled trial.
by: Juliet Mpendo, et al.
Published: (2020-01-01)

Performance of International AIDS Vaccine Initiative African clinical research laboratories in standardised ELISpot and peripheral blood mononuclear cell processing in support of HIV vaccine clinical trials
by: Robert K. Langat, et al.
Published: (2021-02-01)

Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers.
by: Gaudensia Mutua, et al.
Published: (2012-01-01)

A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.
by: Juliet Mpendo, et al.
Published: (2015-01-01)

Enhancing capacity of research ethics review committees in developing countries: The Kenyan example
by: Gloria Manyonyi, et al.
Published: (2014-11-01)

Volunteer motivators for participating in HIV vaccine clinical trials in Nairobi, Kenya.
by: Borna A Nyaoke, et al.
Published: (2017-01-01)

Urinary interleukins (IL)-6 and IL-10 in schoolchildren from an area with low prevalence of Schistosoma haematobium infections in coastal Kenya.
by: Kariuki H Njaanake, et al.
Published: (2023-01-01)

Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.
by: Jaoko, W, et al.
Published: (2008)

Specificity of CD8<sup>+</sup> T-Cell Responses Following Vaccination with Conserved Regions of HIV-1 in Nairobi, Kenya
by: Yehia S. Mohamed, et al.
Published: (2020-05-01)

CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa.
by: Etienne Karita, et al.
Published: (2009-01-01)

Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials.
by: Wendy Stevens, et al.
Published: (2008-04-01)

αEβ7, α4β7 and α4β1 integrin contributions to T cell distribution in blood, cervix and rectal tissues: Potential implications for HIV transmission.
by: Catia T Perciani, et al.
Published: (2018-01-01)

Electroporation (EP)-related technical errors experienced during an HIV vaccine clinical trial conducted in Rwanda and Uganda: lessons learned
by: Bayingana R, et al.
Published: (2012-09-01)

Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers.
by: Mutua, G, et al.
Published: (2012)

Reported willingness to participate in a hypothetical HIV vaccine trial and its translation to actual participation among healthy adults-Experience from Kenya.
by: Delvin Kwamboka Nyasani, et al.
Published: (2018-01-01)

Feasibility of conducting HIV prevention trials among key populations in Nairobi, Kenya
by: Elizabeth Mueni Mutisya, et al.
Published: (2022-12-01)

Cancer in Kenya: types and infection-attributable. Data from the adult population of two National referral hospitals (2008-2012) [version 5; peer review: 2 approved, 2 not approved]
by: Lucy Wanjiku Macharia, et al.
Published: (2019-11-01)

AIDS vaccines and preexposure prophylaxis: is synergy possible?
by: Excler, J, et al.
Published: (2011)

P14-13. Long-term follow-up of study participants in HIV prophylactic vaccine clinical trials in Africa
by: Allen S, et al.
Published: (2009-10-01)

Mucosal Blood Group Antigen Expression Profiles and HIV Infections: A Study among Female Sex Workers in Kenya.
by: Nadia Musimbi Chanzu, et al.
Published: (2015-01-01)

Metabolic and mitochondrial dysregulation in CD4+ T cells from HIV-positive women on combination anti-retroviral therapy.
by: Matrona Akiso, et al.
Published: (2023-01-01)

Metabolic and mitochondrial dysregulation in CD4+ T cells from HIV-positive women on combination anti-retroviral therapy
by: Matrona Akiso, et al.
Published: (2023-01-01)

Reasons for ineligibility in phase 1 and 2A HIV vaccine clinical trials at Kenya AIDS vaccine initiative (KAVI), Kenya.
by: Gloria S Omosa-Manyonyi, et al.
Published: (2011-01-01)

Rethinking the syndemic of tuberculosis and dysglycaemia: a Kenyan perspective on dysglycaemia as a neglected risk factor for tuberculosis
by: Cheryl Kerama, et al.
Published: (2023-04-01)

Understanding adherence to daily and intermittent regimens of oral HIV pre-exposure prophylaxis among men who have sex with men in Kenya
by: Mugo, PM, et al.
Published: (2014)

In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers.
by: Sandhya Vasan, et al.
Published: (2011-01-01)

Low awareness of oral and injectable PrEP among high-risk adolescent girls and young women in Kampala, Uganda
by: Jane Frances Lunkuse, et al.
Published: (2022-05-01)

Creating an African HIV clinical research and prevention trials network: HIV prevalence, incidence and transmission.
by: Anatoli Kamali, et al.
Published: (2015-01-01)

No Substantial Histopathologic Changes in Mops condylurus Bats Naturally Infected with Bombali Virus, Kenya
by: Lauri Kareinen, et al.
Published: (2023-05-01)

Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.
by: Walter Jaoko, et al.
Published: (2010-09-01)

Mobility for maternal health among women in hard-to-reach fishing communities on Lake Victoria, Uganda; a community-based cross-sectional survey
by: Ali Ssetaala, et al.
Published: (2021-09-01)

Recruitment and Follow Up of High Risk HIV Negative Volunteers in Preparation For Vaccine Trials, Kenyan Case
by: Odada Jane, et al.
Published: (2005-12-01)

Latent tuberculosis among household contacts of pulmonary tuberculosis cases in Nairobi, Kenya
by: Susan Odera, et al.
Published: (2020-09-01)

Aflatoxin exposure in children age 6–12 years: a study protocol of a randomized comparative cross-sectional study in Kenya, East Africa
by: Ruth Nabwire Wangia, et al.
Published: (2019-11-01)

A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.
by: Gloria Omosa-Manyonyi, et al.
Published: (2015-01-01)